Effects of Silica and Asbestos Fibres on the Efferocytosis Capacities of Macrophages

Study Overview
=================
Brief Summary
-----------------
Evaluation of the efferocytosis capacities of blood Monocyte Derived Macrophages (MDM) from patients with a history of asbestosis or silica exposure and comparison of these capacities with those of MDM from healthy donors.

Detailed Description
-----------------
Patients with a proven history or current exposure will have 4 EDTA tubes drawn, approximately 24mL of fresh whole blood for efferocytosis assessment and : 2 x 6mL serum tubes for the assessment of Antinuclear Antibody (ANA) positivity, serum high-mobility group box 1 (HMGB1) and osteopontin for patients exposed to asbestos 1 x 6mL serum tube for serum HMGB1 and osteopontin for patients exposed to silica

Official Title
-----------------
Effects of Silica and Asbestos Fibres on the Efferocytosis Capacities of Macrophages

Conditions
-----------------
History of Exposure to Silica or Asbestosis, Positive Testing for ANA as a Marker of Systemic Autoimmune Diseases

Intervention / Treatment
-----------------
* Biological: Blood collection
* Biological: Blood sample
* Biological: Blood sample


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patient older than 18 Yo Addressed to the department of occupational disease With a history of asbestosis or silica exposure evaluated by a dedicated questionnaire and a throughout examination of the history of occupations, according to standard procedures for the follow-up of at risk workers. Persons who received an oral and written information on the protocol and signed the informed consent form Exclusion Criteria: Pregnant or breastfeeding women Subject legally protected (under judicial protection, guardianship), persons deprived of liberty

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Other
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Patients exposed to silica<br> | Biological: Blood collection<br>* 4 EDTA tubes for 24 mL blood collection<br>Biological: Blood sample<br>* 1 drying tube for 6 mL blood collection<br>|
| Active Comparator: Patients exposed to asbestos fibres<br> | Biological: Blood collection<br>* 4 EDTA tubes for 24 mL blood collection<br>Biological: Blood sample<br>* 2 drying tubes for 12 mL blood collection<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Efferocytosis Index (EI) calculation (%) defined as the number of efferocyte MDM / total number of MDM |  | Through study completion, an average of 2 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| EI calculation in patients positive for ANA vs patients negative for ANA |  | Through study completion, an average of 2 years | 
| Serum concentration of HMGB1 and Osteopontin (SPP1) by ELISA |  | Through study completion, an average of 2 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
efferocytosis, macrophages, silica, asbestosis, HMGB1, osteopontin